

**OPPORTUNITY TO INVEST IN A HEALTHCARE & WELLNESS FAMILY OF COMPANIES  
CONSISTING OF: MISSION CRITICAL PHARMACEUTICAL, OTC, CBD, CLINICS &  
INDUSTRIAL HEALTH TECH. FOR BOTH HUMAN & ANIMAL.**



**Luminec  
Holdings**

**EXECUTIVE SUMMARY  
2024 / 2025**



Improve the body's immune system and help stop death from **COVID-19**. Our product can be useful to attack RNA viruses as well as DNA viruses; successful in treating previous Corona Viruses



IP-rich holding company seeking capital for Rx development and Working Capital with Near-term scale from Nutraceutical / OTC products



Free Amino Ion Theory™ drives the technology platform which includes Triamino™, Tafa400™ With Pharmaceutical Peptides, SK-713™; Unique Delivery Technology for Nutraceuticals & Cosmeceuticals, OTC & RX Formulations. IRT360, CRO-50, X-2, Pharmaceutical Grade-CBD,CBN,CBC & CBG Cannabinoid Nano Water Soluble and clinical services



Key applications: Psoriasis, wound healing, skincare, tumors, diabetes, herpes, auto-immune, digestion, insomnia, anxiety, hormones, blood sepsis, heavy metal toxicity and COPD

**\$15M**

**Uses: R&D, S&M  
Clinic CapEx, WC**

**Company Highlights**

- Since 2009
- FDA GRAS Status
- Patent(s) Pending
- Retail, OTC, Rx, Clinical Services
- Triamino™/SK-713™ & Tafa400™/SK-713™ : 2,000+ Patients, 900 Animal cases
- 40+ OTC Products for human and animal (10x animal)
- CRO-50 & X-2: 60,000 + Human & Animal Case Studies
- Diversified Revenue Streams
- Manufacturing US – S. America
- Distribution US – S. America (1,200 salesforce)
- Jet Lasik - refractive and corneal therapeutic surgery services and products

**Investment Merits**

- **A-typical Offering in Biopharma: Company already generating revenue, near-term OTC revenue in scale, and Rx development; diversified rev. stream incl. water treatment**
- **IP Solution Platform has over 100 applications – over 60 human and 30 animal diseases**
- **Serves both Human and Animal markets; agriculture, water treatment on the horizon**
- **OTC Products are natural, FDA GRAS, safer than drinking water**
- **Combined markets served are over \$1 trillion in total opportunity**
- **Management Team and Board includes discipline authorities in Molecular Cell Biology, Organic Chemistry, Medicine, etc.**

**Market Opportunity**

| Massive Economic Impact*                                                                                              | Inefficiencies in Healthcare                                                                                                                                                                                                         |
|-----------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p><b>\$10 Trillion</b><br/>GLOBAL HEALTHCARE INDUSTRY ('22)</p>                                                      | <p> • 55% of Unfilled Prescriptions due to Prohibitive Cost<br/>• \$2.9 Billion R&amp;D Cost per New Drug</p>                                    |
| <p><b>\$2 Trillion</b><br/>GLOBAL OTC + NUTRACEUTICALS + SUPPLEMENT + BEAUTY / SKIN + WOUND CARE INDUSTRIES ('24)</p> | <p> • Average time for FDA NDA is up to 12 years<br/>• Preclinical to Phase 3 Trials</p>                                                         |
| <p><b>\$1.2 Trillion</b><br/>GLOBAL PRESCRIPTION DRUG INDUSTRY ('22)</p>                                              | <p> • Population Aging and Sickenening<br/>• 1 of out every 3 are Pre-diabetic in Certain Countries<br/>• High Level of Un- or Under-insured</p> |
| <p><b>\$143 Billion</b><br/>GLOBAL MEDICAL TOURISM INDUSTRY ('25)</p>                                                 | <p> • Common occurrence of Toxicities and Side Effects<br/>• Overdose</p>                                                                        |
| <p><b>\$350 Billion</b><br/>GLOBAL ANIMAL HEALTH CARE INDUSTRY ('25)</p>                                              |                                                                                                                                                                                                                                      |

## Company Mission


## Platform of Solutions

### Our Global Mission:

**'To Provide Transformational Healing Products and Services that are Safe, Effective, and Affordable to BOTH Human and Animal.'**

*...bringing mission critical health & wellness to the entire world – both developed and emerging – by leveraging innovative Intellectual Property, Best-in-Class Management Team and World Class Partners.*

- John S. Everding, Co-founder



## Retail / OTC Products



## Diversified Business Model Linked by Common Core IP



**How / Where can I afford to get medical or wellness treatment?**



**How do I get Prescription Drugs that are affordable, effective and safe?**



**Where does continued growth, efficiencies and ROI come from?**

### Retail & OTC Products & Services

- FDA GRAS status
- Peptide technology is alternative to Rx
- 40+ human and animal retail, OTC, cosmetic / beauty / skin products available (10 animal products)
- State-of-the-art medical and wellness clinic with GE Healthcare endorsement
- International distribution with name branding
- Revenues within NTM (next twelve months)

### Pharmaceuticals

- Proprietary technologies
- Patents pending
- Live human and animal cases, Lab tests
- Robust potential drug(s) pipeline
- Most pervasive and critical diseases
- Animal and human testing licenses and capabilities

### Venture Capital

- Synergistic ingredient technologies
- Incremental R&D assets
- Incremental domain knowledge accretion
- Supply - / value chain benefit
- Financial upside
- Opportunity #1: Redacted.
- Opportunity #2: Redacted.

# Competitive Advantages

## TRADITIONAL MODEL

1

### COST & TIME.

FDA NDA process can take up to 12 years and cost \$3 billion per drug. Most prescriptions go unfilled due to prohibitive cost.

2

### OVERDOSE, TOXICITIES & ADDICTION.

Global opioid crisis is an epidemic. Occurrences of side-effects and drug addiction are common.

3

### SILOS.

Each new drug development process is a unique, new, standalone process without much recyclability.

4

### OUTSOURCED R&D MODEL FOR PHARMA DRUGS.

Reliant and vulnerable to inconsistencies, delays IP theft and other conflicts of interest.

## LUMINEC DISRUPTIVE MODEL

1

### RETAIL AND OTC PRODUCTS FDA GRAS STATUS.

Affordable and accessible; FDA NDA time process and cost avoided.

2

### UNDERLYING TECHNOLOGIES & PROCESS ARE FDA GRAS.

All-natural ingredients and process. Proven safe by testing and live human and animal administration.

3

### SCALABILITY.

Common denominator of proprietary technologies have broad applicability to treat wide array of diverse diseases and modalities.

4

### COMPLETELY INTEGRATED & ALIGNED R&D LAB CAPABILITIES.

Pharmaceutical R&D Lab is integrated in-house, creating institutional domain, leverageable expertise and inherent scale.

## Case Study: Carcinoma Treated with Triamino™




1-19-06



2-12-06

3-12-06



3-23-06

5-26-06

- **LOCALLY ADVANCED BASI-SQUAMOUS CELL CARCINOMA RIGHT INFRAORBITAL SKIN**
- **TREATED WITH TRI-AMINO**
- **CANCER-FREE AFTER 3 MOS.**

## Luminec Family of Companies

### CORPORATE STRUCTURE



### JET LASIK \*

Refractive and corneal therapeutic surgery services and products

### STRATEGIC PARTNERS / AFFILIATES



### VALUE CHAIN PARTNERS



\*Luminec is expected to have ownership in Jet Lasik.

## Contact Information

**Product & Technical Questions:** Christopher Neville, CEO, Luminec Pharmaceuticals  
[chris@luminecholdings.com](mailto:chris@luminecholdings.com) | +61 433 230 530 (Sydney: GMT+11)

**General Questions:** John Everding, Founder  
[Johnseverding@gmail.com](mailto:Johnseverding@gmail.com) | +01 972 746 6410 (Texas: GMT-5)

Full set of Luminec information available upon request.


# Jet LASIK Profile\*

## JET LASIK


Dr. Paul H Chen, CEO  
1905 Calle Barcelona, #208, Carlsbad, CA 92009

**Background Info:** LASIK corrective vision procedure heals quickly but comes with more complications than does the PRK procedure; PRK on the other hand, is safer but it requires separately scheduled procedures for each eye and a longer healing time.

### Industry Problem:



### Jet Lens Solution:



**Description:** provider of refractive and corneal therapeutic surgery services and products. Creator of Jet Lens™ (Patented), a modified collagen-coated contact lens with a layer of live cultured skin cells.

### Profile:

- Incorporated in CA
- IP Portfolio: Patents, Trade Secrets, Trademarks
- Goal: Seeking \$2.5M to fund Master Cell Bank, file for IDE and conduct clinical trials phases 1 – 2; Seeks \$15M to fund phase 3 clinical trial and BLA filing.


### Patient Benefits:

- Reduce patient's fear of short / long term complications associated with corneal flaps
- Reduce patient's fear of blurry / painful recovery
- Reduce patient's time off of work


### Surgeon Benefits:

- Reduce surgeon's facility opportunity cost associated
- Reduce surgeon's risk of liability
- Marketing "wow" factor

### Process:



### Better safety and quicker recovery at No Additional Cost



| Procedure       | Process         | Complication | Recovery  | Preference |
|-----------------|-----------------|--------------|-----------|------------|
| LASIK           | Flap            | 2-5%         | 1-2 days  | Patients   |
| PRK             | Cell Removal    | 1%           | 1-2 weeks | Surgeons   |
| PRK + JET Lens™ | Cell Transplant | <1%?         | 1-2 days  | Both       |

### Unit Level Economics

- COGS (fully loaded)
  - Lens + collagen + cells + glue ≈ \$68 [at current retail]
  - Apligraf™ comparable 75 mm circle @ \$1,000 [SEC filings, by area] ≈ \$50
- Distribution (FedEx) ≈ \$10-25 per lens
- Cost ≈ \$78 - \$93
- Projected retail \$250-\$350 per lens
- **Gross profit margin 68-76%**

\*Luminec is expected to have ownership in Jet LASIK.